Veteran pharma leader Glenn Gormley joins Aktis Oncology (AKTS) board as director
Rhea-AI Filing Summary
Aktis Oncology appointed Glenn Gormley, MD, PhD, age 72, as an independent Class I director, effective April 15, 2026, with a term running until the 2027 annual stockholder meeting. He will also serve as Co-Chairperson of the newly created Science and Technology Committee.
Under the company’s Non-Employee Director Compensation Policy, Dr. Gormley will receive annual cash fees of $45,000 for Board service and $15,000 for his committee co-chair role, both prorated. He was granted an option to purchase 37,866 shares of common stock under the 2026 Equity Incentive Plan, vesting in equal annual installments over three years, subject to continued service.
The filing also notes that current directors Helen S. Kim and Oleg Nodelman have decided to resign from the Board and all committees, effective May 20, 2026, and that their decisions were not due to any disagreement with the company’s operations, policies, or practices.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Director age: 72 years
Board cash retainer: $45,000 per year
Committee co-chair fee: $15,000 per year
+3 more
6 metrics
Director age
72 years
Age of Glenn Gormley at appointment
Board cash retainer
$45,000 per year
Annual cash compensation for Board service under director policy
Committee co-chair fee
$15,000 per year
Annual cash compensation for Science and Technology Committee co-chair role
Stock option grant size
37,866 shares
Option to purchase common stock granted April 15, 2026
Option vesting period
3 years
Vests in equal annual installments from grant date
Resignation effective date
May 20, 2026
Effective date for resignations of Helen Kim and Oleg Nodelman
Key Terms
Non-Employee Director Compensation Policy, Equity Incentive Plan, Science and Technology Committee, indemnification agreement, +2 more
6 terms
Non-Employee Director Compensation Policy financial
"In accordance with the Company’s Non-Employee Director Compensation Policy (the “Policy”), as a non-employee director..."
Equity Incentive Plan financial
"Dr. Gormley was granted an option under the Company’s 2026 Equity Incentive Plan (the “Plan”) to purchase up to 37,866 shares..."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Science and Technology Committee financial
"appointed to the newly created Science and Technology Committee of the Board (the “Science and Technology Committee”) to serve as Co-Chairperson..."
indemnification agreement regulatory
"The Company also entered into an indemnification agreement with Dr. Gormley in the same form as its standard form of indemnification agreement."
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
forward looking statements regulatory
"This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933..."
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
miniprotein radioconjugate platform technical
"Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes..."
FAQ
What board changes did Aktis Oncology (AKTS) disclose in this 8-K?
Aktis Oncology added Glenn Gormley, MD, PhD, as a Class I independent director and co-chair of its Science and Technology Committee. The company also reported that current directors Helen S. Kim and Oleg Nodelman will resign from the Board effective May 20, 2026.
What compensation will Glenn Gormley receive as an Aktis Oncology (AKTS) director?
Dr. Gormley will receive an annual cash retainer of $45,000 for Board service and $15,000 for co-chairing the Science and Technology Committee, both prorated for time served. He also received a stock option grant to purchase 37,866 shares vesting over three years.
What equity award did Aktis Oncology (AKTS) grant to Glenn Gormley?
Aktis granted Dr. Gormley an option to buy up to 37,866 shares of its common stock under the 2026 Equity Incentive Plan. The exercise price equals the April 15, 2026 Nasdaq closing price, and the option vests in three equal annual installments, subject to continued service.
Why are Helen S. Kim and Oleg Nodelman leaving the Aktis Oncology (AKTS) board?
Helen S. Kim and Oleg Nodelman notified Aktis they will resign from the Board and all committees effective May 20, 2026. The company stated their resignations are not due to any disagreement regarding Aktis’ operations, policies, or practices, indicating an orderly transition.
What is the role of the new Science and Technology Committee at Aktis Oncology (AKTS)?
The Science and Technology Committee is a newly created Board committee focused on scientific and technological matters relevant to Aktis’ business. Dr. Glenn Gormley will serve as Co-Chairperson alongside existing director Ken Herrmann, MD, PhD, strengthening oversight of the company’s radiopharmaceutical platform.
What experience does Glenn Gormley bring to the Aktis Oncology (AKTS) board?
Dr. Gormley has over three decades of biopharmaceutical leadership, including roles as Global Head of R&D and Senior Executive Officer at Daiichi Sankyo and senior positions at AstraZeneca, Novartis, and Merck. He has overseen development of major oncology programs and antibody drug conjugate platforms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
